XtalPi

Founded in 2014, XtalPi is a biotechnology firm specializing in the intersection of artificial intelligence, quantum physics, and cloud computing to revolutionize drug discovery. The company leverages an integrated technology platform to predict the thermodynamic properties and crystalized forms of drug candidates, significantly accelerating pharmaceutical R&D. By utilizing advanced algorithms and digital process development services, XtalPi enables biopharmaceutical partners to optimize therapeutic candidate selection and improve development efficiency. The firm operates at the forefront of intelligent drug design, addressing critical stability challenges that historically hindered pharmaceutical innovation.

XtalPi maintains a robust operational footprint with 1,000-5,000 employees across 3 global locations. The organization supports complex engineering and scientific research, maintaining specialized teams across operations, marketing, and technical development. Meet XtalPi's team to understand the leadership and organizational structure driving these innovations. The company’s B2B service model allows it to integrate into the workflows of global pharmaceutical enterprises, providing scalable solutions for drug development and patent creation. This technical infrastructure supports diverse biopharmaceutical applications, from initial discovery to final process development.

Financially, XtalPi has demonstrated significant growth, reporting annual revenue of $117.7M. The company has secured substantial capital through multiple funding rounds, including a $400.0M Series D in 2021, backed by investors like HOPU Investment Management and OrbiMed. Previous milestones include a $318.8M Series C and a $61.0M Series B, reflecting strong market confidence in its AI-driven drug discovery model. Explore financial highlights for a comprehensive overview of fiscal performance. XtalPi continues to expand its influence, leveraging proprietary technology to redefine modern drug developmentView more...